We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Read MoreHide Full Article
Enanta Pharmaceuticals (ENTA - Free Report) shares soared 5.3% in the last trading session to close at $15.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.8% gain over the past four weeks.
Enanta Pharmaceuticals’ share price gain can likely be attributed to the growing investor sentiment in the company’s advancing pipeline, particularly in respiratory syncytial virus (RSV) and immunology programs. Enanta is now conducting phase III-enabling activities for its lead RSV candidate, zelicapavir, with the FDA while also exploring partnership opportunities. Recent progress in the company’s immunology pipeline, including the dosing of the first participant in the phase I study of EDP-978, a KIT inhibitor being developed for urticaria and other type II inflammatory diseases, also boosted investor confidence.
This biotechnology company is expected to post quarterly loss of $0.46 per share in its upcoming report, which represents a year-over-year change of +56.6%. Revenues are expected to be $17.56 million, up 17.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Enanta Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ENTA going forward to see if this recent jump can turn into more strength down the road.
Enanta Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. MeiraGTx Holdings PLC (MGTX - Free Report) , another stock in the same industry, closed the last trading session 1.5% higher at $9.9. MGTX has returned 2.5% in the past month.
MeiraGTx's consensus EPS estimate for the upcoming report has changed +6.5% over the past month to -$0.43. Compared to the company's year-ago EPS, this represents a change of +15.7%. MeiraGTx currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA - Free Report) shares soared 5.3% in the last trading session to close at $15.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.8% gain over the past four weeks.
Enanta Pharmaceuticals’ share price gain can likely be attributed to the growing investor sentiment in the company’s advancing pipeline, particularly in respiratory syncytial virus (RSV) and immunology programs. Enanta is now conducting phase III-enabling activities for its lead RSV candidate, zelicapavir, with the FDA while also exploring partnership opportunities. Recent progress in the company’s immunology pipeline, including the dosing of the first participant in the phase I study of EDP-978, a KIT inhibitor being developed for urticaria and other type II inflammatory diseases, also boosted investor confidence.
This biotechnology company is expected to post quarterly loss of $0.46 per share in its upcoming report, which represents a year-over-year change of +56.6%. Revenues are expected to be $17.56 million, up 17.6% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Enanta Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ENTA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Enanta Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. MeiraGTx Holdings PLC (MGTX - Free Report) , another stock in the same industry, closed the last trading session 1.5% higher at $9.9. MGTX has returned 2.5% in the past month.
MeiraGTx's consensus EPS estimate for the upcoming report has changed +6.5% over the past month to -$0.43. Compared to the company's year-ago EPS, this represents a change of +15.7%. MeiraGTx currently boasts a Zacks Rank of #3 (Hold).